Prevalence and characteristics of renal artery fibromuscular dysplasia in hypertensive women below 50 years old.
computed tomographic angiography
fibromuscular dysplasia
hypertension
renal artery stenosis
renal duplex
Journal
European journal of clinical investigation
ISSN: 1365-2362
Titre abrégé: Eur J Clin Invest
Pays: England
ID NLM: 0245331
Informations de publication
Date de publication:
Oct 2019
Oct 2019
Historique:
received:
29
10
2018
revised:
29
06
2019
accepted:
17
08
2019
pubmed:
28
8
2019
medline:
2
6
2020
entrez:
28
8
2019
Statut:
ppublish
Résumé
Renal fibromuscular dysplasia (FMD) is typically diagnosed in young hypertensive women. The 2014 European FMD Consensus recommended screening in all hypertensive women <30 yo. However, the prevalence of renal FMD in young/middle-aged hypertensive women remains unclear. The aim of this work was to assess the prevalence and characteristics of renal FMD in hypertensive women ≤50 yo. We retrospectively included all consecutive women aged ≤50 years referred to our Hypertension Unit from 2014 to 2017 and collected standardized information on patient characteristics and screening modalities. Of 1083 incident hypertensive patients, 157 patients fitted with inclusion criteria. The prevalence of renal FMD varied between 3.2% in the whole sample and 7.5% in patients explored by CTA and/or MRA (n = 67). In the subgroup of patients ≤30 yo (n = 32), the corresponding figures were 3.1% and 5.6%. The yearly prevalence of FMD tended to increase over time, in parallel with increased use of CTA/MRA as a first-line imaging modality. Out of 5 patients with renal FMD, 2 were revascularized and 1 had extra-renal FMD. The prevalence of renal FMD in young/middle-aged hypertensive women is probably one order of magnitude higher than previously assumed, in the range of 3%-8%, depending on imaging modalities. While the diagnosis of FMD does not influence short-term management in all patients, it may allow close monitoring and prevention of complications of the disease over time. This analysis provides the rationale for a prospective, multicentre study aiming at determining the cost-effectiveness of systematic screening for renal FMD.
Sections du résumé
BACKGROUND
BACKGROUND
Renal fibromuscular dysplasia (FMD) is typically diagnosed in young hypertensive women. The 2014 European FMD Consensus recommended screening in all hypertensive women <30 yo. However, the prevalence of renal FMD in young/middle-aged hypertensive women remains unclear. The aim of this work was to assess the prevalence and characteristics of renal FMD in hypertensive women ≤50 yo.
METHODS
METHODS
We retrospectively included all consecutive women aged ≤50 years referred to our Hypertension Unit from 2014 to 2017 and collected standardized information on patient characteristics and screening modalities.
RESULTS
RESULTS
Of 1083 incident hypertensive patients, 157 patients fitted with inclusion criteria. The prevalence of renal FMD varied between 3.2% in the whole sample and 7.5% in patients explored by CTA and/or MRA (n = 67). In the subgroup of patients ≤30 yo (n = 32), the corresponding figures were 3.1% and 5.6%. The yearly prevalence of FMD tended to increase over time, in parallel with increased use of CTA/MRA as a first-line imaging modality. Out of 5 patients with renal FMD, 2 were revascularized and 1 had extra-renal FMD.
CONCLUSIONS
CONCLUSIONS
The prevalence of renal FMD in young/middle-aged hypertensive women is probably one order of magnitude higher than previously assumed, in the range of 3%-8%, depending on imaging modalities. While the diagnosis of FMD does not influence short-term management in all patients, it may allow close monitoring and prevention of complications of the disease over time. This analysis provides the rationale for a prospective, multicentre study aiming at determining the cost-effectiveness of systematic screening for renal FMD.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13166Informations de copyright
© 2019 Stichting European Society for Clinical Investigation Journal Foundation.
Références
Plouin P-F, Perdu J, La Batide-Alanore A, Boutouyrie P, Gimenez-Roqueplo A-P. Fibromuscular dysplasia. Orphanet J Rare Dis. 2007;2:28.
Persu A, Giavarini A, Touzé E, et al. European consensus on the diagnosis and management of fibromuscular dysplasia. J Hypertens. 2014;32:1367-1378.
Olin JW, Gornik HL, Bacharach JM, et al. Fibromuscular dysplasia: state of the science and critical unanswered questions: a scientific statement from the American Heart Association. Circulation. 2014;129:1048-1078.
Olin JW, Froehlich J, Gu X, et al. The United States Registry for Fibromuscular Dysplasia: results in the first 447 patients. Circulation. 2012;125:3182-3190.
Plouin P-F, Baguet J-P, Thony F, et al. High prevalence of multiple arterial bed lesions in patients with fibromuscular dysplasia: The ARCADIA Registry (Assessment of Renal and Cervical Artery Dysplasia). Hypertens Dallas Tex. 1979;2017(70):652-658.
Cragg AH, Smith TP, Thompson BH, et al. Incidental fibromuscular dysplasia in potential renal donors: long-term clinical follow-up. Radiology. 1989;172:145-147.
Blondin D, Lanzman R, Schellhammer F, et al. Fibromuscular dysplasia in living renal donors: still a challenge to computed tomographic angiography. Eur J Radiol. 2010;75:67-71.
Hendricks NJ, Matsumoto AH, Angle JF, et al. Is fibromuscular dysplasia underdiagnosed? A comparison of the prevalence of FMD seen in CORAL trial participants versus a single institution population of renal donor candidates. Vasc Med. 2014;19:363-367.
Lewis S, Kadian-Dodov D, Bansal A, Lookstein RA. Multimodality imaging of fibromuscular dysplasia. Abdom Radiol NY. 2016;41:2048-2060.
Bolen MA, Brinza E, Renapurkar RD, Kim E, Gornik HL. Screening CT angiography of the aorta, visceral branch vessels, and pelvic arteries in fibromuscular dysplasia. JACC Cardiovasc Imaging. 2017;10:554-561.
Di Monaco S, Azizi M, Aparicio LS, et al.ESH-Endorsed European/International Fibromuscular Dysplasia Registry: results of the first 609 patients. 28th European Meeting on Hypertension and Cardiovascular Prevention - European Society of Hypertension; Barcelona, 8th -11th June 2018 (abstract).
Van der Niepen P, van Tussenbroek F, Devos H, et al. Visceral fibromuscular dysplasia: from asymptomatic disorder to emergency. Eur J Clin Invest. 2018;48:e13023.
Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604-612.
Lemogoum D, Seedat YK, Mabadeje AF, et al. Recommendations for prevention, diagnosis and management of hypertension and cardiovascular risk factors in sub-Saharan Africa. J Hypertens. 2003;21:1993-2000.
Trinquart L, Mounier-Vehier C, Sapoval M, Gagnon N, Plouin P-F. Efficacy of revascularization for renal artery stenosis caused by fibromuscular dysplasia: a systematic review and a meta-analysis. Hypertension. 2010;56:525-532.
Persu A, Van der Niepen P, Touzé E, et al. Revisiting fibromuscular dysplasia: rationale of the European fibromuscular dysplasia initiative. Hypertens Dallas Tex. 1979;2016(68):832-839.